Search Results for keywords:"Drug Enforcement Administration"

Chattem Chemicals has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of controlled substances. The application, filed on July 20, 2020, lists substances like Marihuana and Tetrahydrocannabinols, which the company plans to create synthetically for distribution and sale. Interested parties can submit comments or request a hearing on this application by April 26, 2021. Written comments should be sent to the DEA in Springfield, Virginia.

The Drug Enforcement Administration (DEA) announced that Mountain Trading LLC has applied to be registered as a bulk manufacturer of marihuana, a controlled substance listed under schedule I. The DEA will evaluate this application, along with others, based on the criteria set out in relevant laws and regulations. Current bulk manufacturers and other applicants can submit comments or objections to this application until April 19, 2021. If registered, the company will produce active pharmaceutical ingredients for research purposes only and must comply with established safeguards against drug diversion.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Linwood A. Starks, D.V.M., proposing to revoke his Certificate of Registration because he is not authorized to handle controlled substances in Texas due to the suspension of his veterinary license. Starks requested a hearing but failed to respond to the allegations, leading to a termination of proceedings and his default. As a result, the DEA Administrator decided to revoke his registration and deny any future applications, as maintaining a DEA registration requires state authorization to handle controlled substances. This decision takes effect on April 21, 2025.

The Department of Justice's Drug Enforcement Administration (DEA) announced a request for public comments on a new information collection plan as per the Paperwork Reduction Act. This collection aims to allow non-registrants to access the CSA Database System to verify DEA registrant status, essential for commerce activities involving controlled substances. The plan targets businesses, not-for-profit institutions, and government entities, with an estimated annual public burden of 250 hours. Public feedback is sought to ensure the necessity, accuracy, clarity, and reduced burden of the information gathering process.

Vici Health Sciences, LLC has applied to become an importer of specific controlled substances to support their research and clinical trials. The Drug Enforcement Administration (DEA) is accepting public comments and objections to this application until February 27, 2025. Interested parties can submit their comments electronically through the Federal eRulemaking Portal. The DEA has specified that this permit will not authorize the import of finished medication forms for sale.

Pharmaron Manufacturing Services (US) LLC has applied to be registered as an importer of certain controlled substances. The Drug Enforcement Administration (DEA) announced this application and is inviting comments and requests for hearings from other registered bulk manufacturers and applicants until April 25, 2025. The company aims to use the imported substances for analytical purposes and production processes but is not authorized for commercial sale of finished dosage forms. The submission of comments should be done electronically through the Federal eRulemaking Portal.

The Drug Enforcement Administration (DEA) issued an order to revoke the registration of Dr. Thomas Andr'e Endicott, a dentist in Utah, due to his lack of authority to handle controlled substances after his state licenses were revoked. The DEA's decision is based on the fact that a practitioner must have state authority to dispense controlled substances to maintain DEA registration. Dr. Endicott did not respond to the order, which was served to him through various means, including email. Consequently, his DEA Certificate of Registration is revoked, and any pending registration applications he has are denied.

S&B Pharma, Inc. has applied to the Drug Enforcement Administration to be registered as a bulk manufacturer of certain controlled substances. The company intends to produce these substances in large quantities for product development and commercial sales. Specifically, S&B Pharma plans to create synthetic versions of Marihuana and Tetrahydrocannabinols. The public and current registered manufacturers have until April 26, 2021, to submit comments or request a hearing on this application.

Myonex Inc has applied for registration as an importer of specific controlled substances, according to a notice from the Drug Enforcement Administration (DEA). The substances are intended for use in clinical trials, research, and analytical purposes, and not for commercial sale of finished dosage forms. Interested parties have until March 29, 2021, to submit written comments or objections, or to request a hearing regarding this application. Written submissions should be directed to the DEA at their office in Springfield, Virginia.

Noramco has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances, including Poppy Straw Concentrate and an intermediate form of Tapentadol. They plan to use these substances to manufacture other drugs for their customers. As part of their application, they also intend to import synthetic cannabidiol and synthetic Tetrahydrocannabinol, while noting that they will not import finished drugs for commercial sale. The public can submit comments or request a hearing on this application by January 6, 2025.